<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616014</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-N01B</org_study_id>
    <nct_id>NCT04616014</nct_id>
  </id_info>
  <brief_title>A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in&#xD;
      Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce&#xD;
      Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events.</measure>
    <time_frame>Week 12</time_frame>
    <description>Safety of Oral Insulin will be measured by the number of treatment-related adverse events according to CTCAE version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in liver fat content</measure>
    <time_frame>Screening(Baseline) and Week 12</time_frame>
    <description>The percent change in liver fat content measured by MRI-Proton Density Fat Fraction from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in liver fibrosis</measure>
    <time_frame>Screening, Week 0, and Week 12</time_frame>
    <description>Percent change in liver fibrosis as measured by FibroScan Elasticity in units of kilo Pascals (kPa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in liver steatosis</measure>
    <time_frame>Screening, Week 0, and Week 12</time_frame>
    <description>Percent change in liver steatosis as measured by FibroScan Controlled Attenuation Parameter (CAP) in units of dB/meter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>ORMD-0801 QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>8 mg QD, daily, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORMD-0801 BD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>8 mg BD, daily in the morning and in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 QD</intervention_name>
    <description>8 mg, QD</description>
    <arm_group_label>ORMD-0801 QD</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 BD</intervention_name>
    <description>8 mg, BD</description>
    <arm_group_label>ORMD-0801 BD</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18-70 years.&#xD;
&#xD;
          -  BMI ≥25.&#xD;
&#xD;
          -  Known type 2 DM according to American Diabetic Association (one of the three needed):&#xD;
             Fasting Plasma Glucose ≥126 mg/dl or 2h postprandial (PG) following 75g OGTT ≥200&#xD;
             mg/dl or HbA1c &gt; 6.5%28 or on treatment with metformin only or metformin in addition&#xD;
             to no more than two of the following medications sulfonylurea, DPP-4 inhibitors, GLP-1&#xD;
             receptor agonists, Thiazolidinediones (TZDs).&#xD;
&#xD;
          -  Diagnosis of NAFLD by non-invasive determination of hepatic steatosis grade S1,&#xD;
             defined as hepatic steatosis&gt;8%. by MRI- PDFF and CAP FibroScan ≥ 238 dB/m.&#xD;
&#xD;
          -  Liver enzyme abnormalities: ULN≤5 times.&#xD;
&#xD;
          -  Fibrosis score 21≤F≤3 as defined by FibroScan measurement (Liver stiffness&#xD;
             measurement, LSM) of 6 ≤ LSM ≤ 12 kPa.&#xD;
&#xD;
          -  Signature of the written informed consent.&#xD;
&#xD;
          -  Negative urineserum pregnancy test at Screening study entry for women of childbearing&#xD;
             potential (WCBP).&#xD;
&#xD;
          -  Women of childbearing potential (WCBP) must have a negative urine pregnancy test&#xD;
             result prior to the start of the run-in period and at. initiation of A negative urine&#xD;
             and serum pregnancy test must be obtained prior to active dosing. Males and females of&#xD;
             childbearing potential must use two methods of contraception (double barrier method),&#xD;
             one of which must be an acceptable barrier method from the time of screening to the&#xD;
             last dosing study visit (22 weeks). Barrier methods of contraception include male&#xD;
             condoms plus spermicide, diaphragm with spermicide plus male condom, cervical cap with&#xD;
             spermicide plus male condom, or oral contraceptives. Acceptable methods of birth&#xD;
             control include abstinence, oral contraceptives, surgical sterilization, vasectomy,&#xD;
             the contraceptive patch, and the contraceptive ring. If a subject is not usually&#xD;
             sexually active but becomes active, he or his partner should use medically accepted&#xD;
             forms of contraception. Sperm donations will not be allowed for the duration of the&#xD;
             study and for 90 days after the last dose of study drug.&#xD;
&#xD;
          -  Females of non-childbearing potential are defined as postmenopausal who a) had more&#xD;
             than 24 months since last menstrual cycle with menopausal levels of FSH (FSH Level &gt;&#xD;
             40), b) who are surgically menopausal (surgical sterility defined by tubal occlusion,&#xD;
             bilateral oophorectomy, bilateral salpingectomy or hysterectomy).&#xD;
&#xD;
          -  For hypertensive patients, hypertension must be controlled by stable dose of&#xD;
             anti-hypertensive medication for at least 2 months prior to screening (and the stable&#xD;
             dose can be maintained throughout the study) with BP &lt; 150/&lt;95 mmHg&#xD;
&#xD;
          -  Patients previously treated with vitamin E (&gt;400IU/day), Polyunsaturated fatty acid&#xD;
             (&gt;2g/day) or Ursodeoxycholic acid fish oil can be included if drugs are stopped at&#xD;
             least 3 months prior to enrolment and up to the end of the study.&#xD;
&#xD;
          -  Glycaemia must be controlled (Glycosylated Hemoglobin A1C ≤8.5%) while any HbA1c&#xD;
             increment should not exceed 1% during 6 months prior to enrolment).&#xD;
&#xD;
          -  Patients who are willing to participate in the study, have to have their own&#xD;
             self-monitoring blood glucose devices.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active (acute or chronic) liver disease other than NASH (e.g. viral&#xD;
             hepatitis, genetic hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency,&#xD;
             alcohol liver disease, drug induced liver disease) at the time of enrolment.&#xD;
&#xD;
          -  ALT or AST &gt; 5 times ULN.&#xD;
&#xD;
          -  Abnormal synthetic liver function (serum albumin ≤3.5gm%, INR &gt;1.3).&#xD;
&#xD;
          -  Known alcohol and/or any other drug abuse or dependence in the last five years.&#xD;
&#xD;
          -  Weight &gt;120 Kg (264.6 lbs.).&#xD;
&#xD;
          -  Known history or presence of clinically significant, cardiovascular, gastrointestinal,&#xD;
             metabolic (other than diabetes mellitus), neurologic, pulmonary, endocrine,&#xD;
             psychiatric, neoplastic disorder or nephrotic syndrome.&#xD;
&#xD;
          -  History or presence of any disease or condition known to interfere with the&#xD;
             absorption, distribution, metabolism or excretion of drugs including bile salt&#xD;
             metabolites (e.g. inflammatory bowel disease (IBD), previous intestinal (ileal or&#xD;
             colonic) operation, chronic pancreatitis, celiac disease or previous vagotomy.&#xD;
&#xD;
          -  Weight loss of more than 5% within 6 months prior to enrolment.&#xD;
&#xD;
          -  History of bariatric surgery.&#xD;
&#xD;
          -  Uncontrolled blood pressure BP ≥150/≥95.&#xD;
&#xD;
          -  Non-type 2 DM (type 1, endocrinopathy, genetic syndromes etc.).&#xD;
&#xD;
          -  Patients with HIV.&#xD;
&#xD;
          -  Daily alcohol intake &gt;20 g/day (2 units/day) for women and &gt;30 g/day (3 units/day) for&#xD;
             men.&#xD;
&#xD;
          -  Treatment with anti-diabetic medications other than metformin and more than two of the&#xD;
             following medications sulfonylurea, DPP-4 inhibitors, GLP-1 receptor agonists, TZDs.&#xD;
&#xD;
          -  Metformin, fibrates, statins, not provided on a stable dose in the last 6 months.&#xD;
&#xD;
          -  Patients who are treated with valproic acid, Tamoxifen, methotrexate, amiodarone.&#xD;
&#xD;
          -  Chronic treatment with antibiotics (e.g. Rifaximin).&#xD;
&#xD;
          -  Homeopathic and/or Alternative treatments. Any treatment must be stopped before the&#xD;
             screening period.&#xD;
&#xD;
          -  Uncontrolled hypothyroidism defined as Thyroid Stimulating Hormone &gt;2X the upper limit&#xD;
             of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to&#xD;
             screening is permitted.&#xD;
&#xD;
          -  Patients with renal dysfunction: eGFR&lt; 40 ml/min.&#xD;
&#xD;
          -  Unexplained serum creatinine phosphokinase (CPK) &gt;3X the upper limit of normal (ULN).&#xD;
             Patients with a reason for CPK elevation may have the measurement repeated prior to&#xD;
             enrolment; a CPK retest &gt; 3X ULN leads to exclusion.&#xD;
&#xD;
          -  Subjects meeting criteria for contraindication for MRI - including the following:&#xD;
&#xD;
               -  History of severe claustrophobia impacting ability to perform MRI during the&#xD;
                  study, even despite mild sedation/treatment with as anxiolytic.&#xD;
&#xD;
               -  Subjects with metal implants, devices, paramagnetic objects contained within the&#xD;
                  body and excessive or metal-containing tattoos.&#xD;
&#xD;
               -  Subjects unable to lie still within the environment of the MRI scanner or&#xD;
                  maintain a breath-hold for the required period to acquire images, even despite&#xD;
                  mild sedation/treatment with an anxiolytic.&#xD;
&#xD;
          -  Subject participated in a clinical research study involving a new chemical entity&#xD;
             within 4 weeks of study entry.&#xD;
&#xD;
          -  Known allergy to soy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Kidron, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oramed, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Kidron, PhD</last_name>
    <phone>+972 50-766-5423</phone>
    <email>miriam@oramed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meir Silver, Ph.D.</last_name>
    <phone>+972-54-633-5855</phone>
    <email>meir@oramed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Muylaert</last_name>
      <phone>+3293329459</phone>
      <email>delphine.muylaert@uzgent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010 Aug;53(2):372-84. doi: 10.1016/j.jhep.2010.04.008. Epub 2010 May 7.</citation>
    <PMID>20494470</PMID>
  </reference>
  <reference>
    <citation>Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30. Review.</citation>
    <PMID>21623852</PMID>
  </reference>
  <reference>
    <citation>Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008 Jun;47(6):1916-23. doi: 10.1002/hep.22241.</citation>
    <PMID>18433022</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

